ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

1,7700

23-декабря-24 15:45:00

15 мин. задержка

Акции

-0,0800

-4,32%

Сегодняшний диапазон

1,7580 - 1,8500

ISIN

N/A

Источник

NASDAQ

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 май 2024 15:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

04 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

26 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

21 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

19 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

12 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

08 мар 2024 07:50:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

01 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 янв 2024 15:15:20 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

13 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

13 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

07 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

06 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

06 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

02 ноя 2023 15:00:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

27 окт 2023 08:25:00 Источник Nasdaq GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

04 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.